Arbutus Wins FDA Clearance to Resume Hepatitis B Drug Trials
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has received clearance from the U.S. Food and Drug Administration to resume clinical development of its experimental hepatitis B treatment AB-101 in …
Arbutus Wins FDA Clearance to Resume Hepatitis B Drug Trials Read More